The SHOCKING Truth About Ozempic Side Effects (And How To Avoid Them)

Tina has used compounded peptides throughout her 30-year naturopathic career. She applies the same slow-titrate-to-tissue-saturation approach she uses with thyroid hormone and bioidentical estrogen. The compounded form of semaglutide costs pennies per day versus $1,800/month for pharma Ozempic. A JAMA study cited in the episode suggests production cost is $0.75–72/month. The FDA is actively trying to shut down compounding pharmacies making GLP-1 peptides — Tina attributes this to pharmaceutical industry pressure rather than safety concerns.

Hyman calls strength training 'non-negotiable' and 'period' for metabolic health and longevity. Tina says she 'will pull dispensing this if you don't strength train.' Both guests reference the same data: GLP-1 at pharmacologic dose without strength training + adequate protein produces the worst-case outcome — rapid weight loss, muscle wasting, then full fat regain with metabolic damage when drug is discontinued. Tina monitors patients by direct palpation of muscle integrity at each visit — a chiropractor's tool that gives real-time feedback on whether the patient's body composition is responding appropriately.

Hyman and Tina both emphasize that Nova Nordisk's own instructions for Ozempic admit the drug requires exercise and dietary shift to avoid the 'huge disaster' of significant muscle loss. The company's own data acknowledges this risk, yet the standard prescribing practice rarely enforces or even monitors it. Tina's approach inverts the pharma model: keep the dose low enough that the patient still wants to eat enough protein, then let the GLP-1 do its targeted visceral-fat work rather than creating a global calorie crash.

Tina uses multiple peptides in her practice alongside GLP-1: BPC-157 for tissue repair and injury healing, thymosin alpha-1 for immune support, and others for brain health. She analogizes GLP-1 to bioidentical hormones: thyroid hormone replacement, estrogen replacement, testosterone optimization — all are physiologic replacements for things the body makes naturally but is making insufficiently. She finds the combination approach — GLP-1 + hormones + targeted peptides + lifestyle — produces outcomes impossible to achieve with any single intervention.

Hyman's concern about the 'lifetime drug' framing: the weight regain on drug discontinuation is used as proof that the drug is needed forever. But it's actually proof that no lifestyle change was made while on the drug. Tina's cycling approach proves the concept: her metabolically optimized patients cycle off without gaining weight back — demonstrating the drug was helping them achieve a transformation, not substituting for one. The Novo Nordisk business model depends on lifetime prescribing; the functional medicine model aims to make the drug unnecessary.

Hyman references 'a company called Pendulum' that has a product specifically formulated to help unlock GLP-1 pathways naturally through targeted probiotic and prebiotic combinations. He also notes that True Med (now True Med HSA platform) helps patients use HSA/FSA dollars for these lifestyle interventions — making them more accessible. The broader point: the pharmaceutical solution to GLP-1 deficiency is one path, but the physiologic path (rebuilding the metabolic environment that produces adequate GLP-1 naturally) is the correct long-term solution.

Tina describes patients on her micro-dose GLP-1 protocol who, once neuroinflammation starts coming down and they lose a few pounds, spontaneously begin asking 'Doc, what should I do for exercise? What should I be eating?' The HPA axis improvement drives a naturally increased desire to implement healthy behaviors — an effect that doesn't happen when high-dose GLP-1 simply crashes appetite. Tina's approach aims to create a positive feedback loop: micro-dose GLP-1 reduced neuroinflammation better brain function more motivation to implement lifestyle change more endogenous GLP-1 lower dose needed.

Tina explains that when GLP-1 is absent, leptin and ghrelin receptors don't function correctly at the cellular level — they 'don't even come to the surface.' This means GLP-1 deficiency is not just about appetite: it's about whether the brain receives accurate energy-status signals at all. The causes of acquired GLP-1 deficiency appear to include vagal nerve damage, leaky gut, microbiome disruption from ultra-processed food, environmental toxins, and possibly epigenetic programming from maternal metabolic dysfunction. The genetic SNP finding from a single large functional medicine diabetes practice (95% of patients carrying the mutation) hasn't been replicated at scale but suggests the issue may be substantially more genetic than current mainstream obesity science acknowledges.

Tina spent months researching GLP-1's regenerative properties before using it clinically. She found studies showing GLP-1 impact on neuroinflammation, Alzheimer's, Parkinson's, joint cartilage, ligament repair, and pancreatic beta-cell regeneration. She also notes that GLP-1 agonists are being studied for their anti-inflammatory properties: by reducing intake of ultra-processed food, users experience reduced neuroinflammation and improved serotonin/dopamine signaling as a downstream effect — which may explain the observed reductions in depression and suicidal ideation in some trials. Hyman adds that the EU investigation into suicidal ideation 'came back and said it was not an issue' but acknowledges an ongoing investigation suggests the picture is not fully settled.

Tina analogizes to her long-standing practice with other hormones: she titrates patients slowly upward until they achieve tissue saturation and symptom resolution, then holds at the minimum effective dose. She applies the same logic to GLP-1. She also notes that for severely metabolically busted patients the dose can be slightly higher than micro-dose (as with her father, who is morbidly obese) but still well below the standard pharma protocol — and even at that higher-but-still-low dose, cognitive function improved within weeks and hope returned. The compounded form is available for pennies per day versus $1,800/month for pharma-brand Ozempic. A JAMA study cited by Hyman suggests production cost for GLP-1 drugs is $0.75–$72/month, versus U.S. list prices of $1,800/month.

The analogy Tina draws: just as insulin-resistant diabetics need larger insulin doses to lower blood sugar while metabolically healthy people need only a tiny amount, GLP-1 works more efficiently in systems that aren't globally dysregulated. The pathway to using GLP-1 well is to improve the metabolic foundation first (protein, strength training, sleep, stress, microbiome), then GLP-1 can operate at micro-doses for targeted support. The reverse — slam a toxic system with high-dose GLP-1 — produces the crash-course-calorie-deficit phenotype: rapid weight loss, muscle wasting, nutrient deficiencies, and rebound weight gain after discontinuation.

The parallel Tina draws is to bioidentical hormone cycling: hormones like estrogen and progesterone are often cycled rather than run continuously. GLP-1 operates similarly as a signaling peptide. The caveat: cycling only works if the patient has genuinely rebuilt their metabolic foundation. For someone like Tina's father (morbidly obese, two mini-strokes, can't exercise) the goal is still as-low-as-possible dose but the cycling approach may come later when functional capacity improves.

Hyman closes the episode by noting that for people facing testosterone deficiency, lifting weights will raise testosterone which in turn raises GLP-1 — creating a positive cascade. Stopping eating sugar and starch also raises GLP-1. Berberine, which Hyman has covered separately as 'natural metformin,' acts on overlapping metabolic pathways. The implication is that the GLP-1 system is not broken irreparably — it's been suppressed by an ultra-processed food environment, sedentary lifestyle, and chronic stress, and it responds to reversal of those inputs.